Cannabinoid type 1 receptor blockade promotes mitochondrial biogenesis through endothelial nitric oxide synthase

Laura Tedesco1, Alessandra Valerio, Cristina Cervino

  • 1Integrated Laboratories Network, Center for Study and Research on Obesity, Department of Pharmacology, Chemotherapy and Medical Toxicology, School of Medicine, Milan University, Milan, Italy.

Diabetes
|May 15, 2008
PubMed
Abstract

Insights

Cannabinoid type 1 (CB1) receptor blockade boosts mitochondrial biogenesis in white adipocytes by increasing endothelial NO synthase (eNOS) expression, preventing diet-induced fat accumulation without affecting food intake.

Area of Science:

  • Metabolism and Endocrinology
  • Cellular Biology
  • Obesity Research

Background:

  • Cannabinoid type 1 (CB1) receptor blockade reduces body weight and adiposity, but the mechanism remains unclear.
  • Endothelial NO synthase (eNOS)-produced nitric oxide (NO) is known to promote mitochondrial biogenesis and function in adipocytes.

Purpose of the Study:

  • To investigate whether CB1 receptor blockade enhances eNOS expression and mitochondrial biogenesis in white adipocytes.
  • To elucidate the role of eNOS in mediating the effects of CB1 receptor blockade on adipocyte metabolism.

Main Methods:

  • Selective pharmacological blockade of CB1 receptors using SR141716 (rimonabant) in primary mouse white adipocytes.
  • Assessment of eNOS expression and mitochondrial biogenesis in white adipose tissue (WAT) and isolated adipocytes from CB1 receptor-deficient (CB1(-/-)) mice and mice chronically treated with SR141716 on standard or high-fat diets.

Main Results:

  • SR141716 treatment upregulated eNOS expression and increased mitochondrial DNA, mRNA levels of biogenesis genes, mitochondrial mass, and function in cultured white adipocytes.
  • These effects were dependent on eNOS induction, as confirmed by siRNA-mediated knockdown.
  • In high-fat diet-fed mice, CB1 receptor deletion or SR141716 treatment normalized reduced eNOS expression and mitochondrial biogenesis in WAT, preventing weight gain and adiposity.

Conclusions:

  • CB1 receptor blockade promotes mitochondrial biogenesis in white adipocytes via eNOS induction.
  • This mechanism contributes to the prevention of high-fat diet-induced obesity and fat accumulation, independent of changes in appetite.

Related Concept Videos

Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
Nitric Oxide Signaling Pathway01:28

Nitric Oxide Signaling Pathway

Nitric oxide (NO), an inorganic gas, acts as a potent second messenger in most animal and plant tissues. NO diffuses out of the cells that produce it and enters the neighboring cells to generate a downstream response. NO synthase (NOS) catalyzes NO production by the deamination of the amino acid arginine. There are three isoforms of NOS. Endothelial cells have endothelial NOS (eNOS), nerve and muscle cells have neuronal NOS (nNOS), and macrophages produce inducible NOS (iNOS) upon exposure to...
Adrenergic Agonists: Indirect-Acting Agents01:25

Adrenergic Agonists: Indirect-Acting Agents

Indirect-acting adrenergic agonists potentiate the effects of endogenous catecholamines through different mechanisms without directly binding to adrenoceptors.
One mechanism involves depleting stored catecholamines by displacing them from synaptic vesicles. These agents, known as "displacers," are transported into vesicles at the expense of noradrenaline. Examples include amphetamine and tyramine, which lack a catechol moiety, resulting in prolonged action, improved oral bioavailability, and...